Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia (Accredited)


The MYD88 p.Leu265Pro (L265P) variant is found in >90% of lymphoplasmacytic lymphoma (LPL) patients, however, it is not specific to LPL, nor required for diagnosis. In a substantial subset of patients with LPL (~95%), the clinical features of disease include the presence of an IgM monoclonal gammopathy, indicative of Waldenstrӧm Macroglobulinaemia (WM).


MYD88 is a signalling protein, involved in the NF-Κß cascade. The presence of the MYD88 p.Leu265Pro (L265P) variant results in constitutive activation of the signalling cascade, promoting cellular survival and oncogenesis. Bruton Tyrosine Kinase (BTK) inhibitors, such as Ibrutinib, have been shown to be effective in the treatment of WM due to inhibition of the NF-Κß cascade downstream of MYD88. Patients without the MYD88 p.Leu265Pro variant have an adverse prognosis and lower response to Ibrutinib, thus testing for the variant is important from a prognostic and therapeutic standpoint (Treon et al., 2018).


For this programme, participants are provided with lyophilised cell line based EQA material for MYD88 p.Leu265Pro variant analysis. Participants are required to test the lyophilised material and to submit qualitative results, together with details of methodology. Instructions for storage, reconstitution and use of the lyophilised samples are provided with trial distributions. Two trials are issued per annum, with each trial consisting of two samples. The programme is qualitative; however, optional quantitative information (variant allele frequency) may also be submitted for educational purposes.


Trials for this programme are live/open for a minimum of 4 weeks.

Please Note: Trials issued/closing in August or December are extended by 1 week.


Pre-issue and post-closure testing of samples for this programme is subcontracted, although the final decision about sample suitability lies with the EQA provider; no other activities in relation to this EQA programme are subcontracted.


***New for 2024-2025***

UK NEQAS LI have submitted the Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia programme to our accrediting body (UKAS) for accreditation and hope for its inclusion in our formal scope of accreditation in 2024/25. This will allow for the implementation of formal performance monitoring. 


To register for this programme, please click here.

LPLWM 232402 Coverletter
LPLWM 232402 coverletter.pdf
Adobe Acrobat document [91.9 KB]
Example LPLWM Report
LPLWM 222302 v1.0.0 Example Report.pdf
Adobe Acrobat document [229.5 KB]
Lymphoplasmacytic Lymphoma Waldenstrom Macroglobulinemia Performance Monitoring System
Lymphoplasmacytic Lymphoma Waldenstrom [...]
Adobe Acrobat document [92.1 KB]
Print | Sitemap

Follow Us Online
Facebook Twitter LinkedIn Youtube


Last updated 16/05/2024 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information please click here.

Please click here for our privacy policy.

The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).